Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T12:50:29.777Z.
Calculation as of: 2026-10-06T12:50:29.777Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$867.60M
PS Ratio
30.20
TTM Avg
20.29
3Y Avg
47.07
5Y Avg
47.07
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $866.15M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | 30.20 | 20.29 | 47.07 | 47.07 |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | 7.16 | 8.02 | 9.17 | 9.17 |
| Alumis Inc. (ALMS)vs › | $844.28M | 114.12 | 174.59 | 129.38 | 129.38 |
| Ardelyx, Inc. (ARDX)vs › | $837.43M | 1.86 | 3.32 | 5.97 | 11.95 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | N/A | N/A | N/A | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | 6.86 | 6.23 | 9.08 | 36.05 |
| Bioventus Inc. (BVS)vs › | $915.95M | 1.57 | 1.18 | 0.98 | 0.92 |
| InMode Ltd. (INMD)vs › | $812.20M | 2.17 | 2.45 | 3.11 | 6.00 |
| HealthStream, Inc. (HSTM)vs › | $921.45M | 2.87 | 2.39 | 2.83 | 2.81 |
The four-quarter calculation detail is unavailable for this stored observation.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
